Big business trends
big player
Future Fields launches the first recombinant prolactin protein based on Drosophila.
Yuguan Biologics and WuXi Vaccines are accelerating the development of innovative bacterial vaccines.
imagindairy realizes large-scale production of dairy protein.
amsilk joins hands with 21stBIO accelerates the industrial mass production of spider silk protein fiber materials.
Cathay Biotech and 3P set up a joint venture to develop bio-based composites.
Mnext launches development project for pulse-based alternative proteins and by-products.
Ayana Bio has partnered with Wooree Green Science to develop plant cell derivative components.
Syngenta and Enko accelerate the development of innovative crop protection solutions.
02 Major Enterprise Trends
Synthetic biology
Future Fields launches the first recombinant prolactin protein based on Drosophila.
On January 16, Canadian biotech company Future Fields launched its first oneDrosophila-based recombinant human prolactin (PRL-FC)., which is the first to be obtained from a commercial Drosophila expression systemProlactin protein。Future Fields' recombinant human prolactin has:High activity, applicable toCell cultureand preclinical application of the test, without compromising the quality of the productThe lowest in the marketAt the same time, it can be used for insufficient lactation of lactating mothers, improving the composition of breast milk, and the development and production of dairy productsFood ingredientsSpecial infant formula, immune cells (dendritic cells, lymphocytes), mammary epithelial cells and nerve cell studies, pancreatic islet cells and cell protection in liver transplantation, etc.
Synthetic biology
Yuguan Biologics and WuXi Vaccines are accelerating the development of innovative bacterial vaccines.
FocusInnovative bacterial vaccine research and developmentThe company has signed a technology development agreement with WuXi Vaccines, a leading global vaccine CDMO company, to accelerate the advancement of the companyInnovative bacterial vaccinesdevelopment. According to the agreement, Yuguan Biologics will leverage WuXi Vaccines' deep technical expertise, rich regulatory experience, first-class quality system, advanced CMC development capabilities and abundant GMP production capacity in the field of vaccines to accelerate the advancementInnovative bacterial vaccine pipelinesproduction, clinical application and international layout. The two sides will make full use of their respective advantages and resources to cooperate to achieve breakthroughs and win-win results in the field of innovative bacterial vaccines.
Synthetic biology
imagindairy realizes large-scale production of dairy protein.
The Israeli synthetic biology company imagindairy has announced that it has been realizedLarge-scale production of milk proteinand** comparable to traditional dairy products. At the same time, the company will acquire an industrial-scale plant in the Middle East, enabling its production capacity to be reached100,000 litersand plans to increase production in the next 1-2 years2 times。imagindairy passedPrecision fermentationProduced sustainably and without animal ingredientsMilk protein - lactoglobulin, which is produced by an AI-driven microbial community-based production method (Aspergillus oryzae). In addition to this, the company is also working on other proteins, including casein, which accounts for the protein content of dairy products) and other whey proteins, such as whey protein, which accounts for about the amount of cow's whey）。After the company self-confirmed its Generally Accepted Safety (GRAS) status in August 2023, the ingredient received FDA regulatory approval in the form of a "no doubt" letter two weeks ago.
Bio-based new materials
amsilk joins hands with 21stBIO accelerates the industrial mass production of spider silk protein fiber materials.
On January 17th,Spider silk proteinAmsilk, an advanced materials company, and 21st., a leader in bioproductionBio collaborated to accelerate the industrial mass production of Amsilk's spider silk protein, increasing the production capacity from a few kilograms to several tons. Meanwhile, 21stBio has developed oneNew protein-producing strains, this strain consists of highly specializedPrecision fermentation microorganismsto ensure that amsilk can meet the needs of production from the laboratory to the industrial scale. The new strain ensures extracellular expression of arachnoid proteins, resulting in higher yields, higher efficiency, and high productivity levels with low production costs. Amsilk's spider silk protein has:Fully biodegradablewithBiocompatible properties, based onRenewable, plant-based raw materialsAmsilk fiber does not contain any animal-derived substances and reduces CO2 greenhouse gas emissions by up to compared to other protein fibers, reduced land and water useThese high-performance properties make it widely used in the textile, home care, biomedical and automotive industries. Amsilk has developed a wide range of use cases for its spider silk proteins, from developmentSpider silk protein fibersto convert proteins into beads, gels and solutions to unleash the power of their coating effects.
Bio-based new materials
Cathay Biotech and 3P set up a joint venture to develop bio-based composites.
On January 16, Cathay Biotech and South Korea 3Pcom Company signed an agreement to establish a joint venture company, and the joint venture company will be committed to:Development of thermoplastic bio-based polyamide compositesapplications, including hydrogen storage and transportation, urban air mobility, wind turbine blades, and more. The cooperation aims to promote new energy, transportation and other fieldsNew materialsto provide technical support for achieving net-zero emissions. Cathay Biotech is based on synthetic biology and other disciplines, using biomanufacturing technology, engaged in:New bio-based materialsR&D, production and sales, the company's business is mainly focused onPolyamide industry chainIt has a number of bio-based long-chain diacids, bio-based pentanediamines, bio-based polyamides, etcLarge-scale industrial biotechnology。3p.com was founded by Professor Ha Sung-kyu of Hanyang University in fiber reinforcementComposite green energyStorage and transportation fieldIndustry-leading innovative design and manufacturing capabilities.
Alternative proteins
Mnext launches development project for pulse-based alternative proteins and by-products.
The MNEXT Bioresources and Energy Research Group has released a new project".Columbus protein", the project is committed to:Protein conversion, by fromAnimal protein productionShift to morePlant protein production, focusing on optimizing the use of protein-rich crops and the by-products produced in the process. The project focuses on legumes (such as fava beans and lupins), which are the main components of plant protein production in the Netherlands, and uses them for the fruit juice and wet by-products of the processing of pulses and pulsesFibrous part of plant residuesConducts research on a variety of applications, including insulation and building materials, biocomposites, and paper, with a focus on personal care products and bioplastics in the juice direction.
Cell culture
Ayana Bio has partnered with Wooree Green Science to develop plant cell derivative components.
Ayana Bio and Wooree Bio's subsidiary, Wooree Green Science, have entered into a joint development agreement for joint productionPlant cell-derived components, with a focus on saffron for use in health and wellness products. Both sides aim to exploitPlant cell culture technologySolve the saffron chain challenge and make saffron in the Korean marketBeneficial botanical ingredientsEasier access and lower cost. Ayana BioPlant Cell Advantage technologyA series will be producedBiologically active substances, with a higher efficacy than biologically active substances found in nature. The ingredients developed by both companies will be used in a diverse range of industries such as food, beverage, cosmetics and pharmaceuticals.
Plant protection
Syngenta and Enko accelerate the development of innovative crop protection solutions.
On January 18, Syngenta Crop Protection and Enko announced that they had jointly discovered a R&D platformNew chemicalsto control the cropsFungal diseases。This new chemistry has a new mode of action designed to target fungal diseases that can destroy cereal crops. This breakthrough was achieved by screening in the DNA-encoded library of ENKOBillions of chemical molecules, which is then obtained using AI and machine learning models to identify effective selective molecules. The platform significantly reduces the time required for R&D while ensuring that molecules meet specific safety standards. The discovery of the fungicide is part of a multi-year collaboration between Syngenta and Enko to bring new, low-cost, safe and sustainable products to farmers around the worldCrop protection solutions。At present, the two sides have entered the next stage of cooperation, mainlyOptimize the properties of the biocideand rigorously tested for safety and efficacy; At the same time, a new agreement will be signed on the basis of the success of the cooperation on fungicides, looking for oneNew chemical herbicides
TechCube is an innovation platform focusing on technology commercialization in the field of biotechnology;
Promote the deep integration of source innovation and industry;
Walk with scientists, entrepreneurs, investors and stakeholders;
Continue to build a company that leads the transformation of the biological industry.